Has Alvotech (NasdaqGM:ALVO) Fallen Below Fair Value After Its Deal?

Alvotech stock has fallen about 50% over the past three years, yet the valuation checks currently lean cheap and the market is reacting positively to fresh licensing deals and regulatory progress.

• Over the past three years the share price is down about 50%, which means any case for owning Alvotech today rests heavily on a potential recovery from a deep drawdown.

• A recent licensing agreement with Lotus Pharmaceutical for two biosimilars and ongoing work toward U.S. approvals can support expectations for future revenue, while the company’s need for continued funding and regulatory execution may influence how much value investors ascribe to that pipeline.

• The broader valuation checks currently lean cheap on Alvotech, with the company screening as undervalued on most metrics and earning a value score of 5 that suggests the market price may be below what the fundamentals imply.

The issue now is whether that apparent discount in Alvotech shares fairly reflects the risks around its biosimilar portfolio or leaves room for upside if execution goes to plan.

Capture this potential recovery theme in context by comparing Alvotech with other undervalued stocks using our hand picked 44 high quality undervalued stocks.

Is Alvotech Still Cheap on Sales?

The P/S ratio fits Alvotech well because the company is still focused on scaling revenue rather than generating consistent earnings.

On this measure, Alvotech trades at about 3.6x P/S, compared with a Biotechs industry average of around 13.2x and a peer group average of roughly 16.2x. The fair P/S ratio implied by the model is 5.1x, which is higher than where the stock trades today but still below the broader peer averages. That suggests the framework already accounts for Alvotech’s execution and funding risks, yet still points to a gap between the current multiple and what its revenue profile might justify.

Despite recent licensing news and financing updates, the current P/S still prices Alvotech at a discount to both the tailored fair ratio and sector benchmarks.

On the P/S multiple, Alvotech stock appears undervalued relative to both its modelled fair ratio and typical Biotech peers.

See what the numbers say about this price — find out in our valuation breakdown.

The Alvotech Narrative: What Would Justify Today’s Price?

Simply Wall St Narratives pick up where this Alvotech valuation puzzle leaves off and explain what kind of future growth, margins and earnings would need to appear for the stock to be worth materially more or less than today’s price on the Community page. Each narrative links its number to a clear view on how Alvotech’s growth, profitability and risks might evolve, which you can revisit as fresh results and regulatory updates arrive.

Community views on Alvotech sit far apart, with one side focused on upside from biosimilars and the other fixated on execution and balance sheet risk.

Bull case: 14% undervalued

“Strengthened strategic partnerships (for example, with Advanz Pharma, Teva, and Dr. Reddy’s) and an expanding distribution footprint enable Alvotech to rapidly access new regions and patient pools…”

Read the full Bull Case to see why Alvotech could be undervalued

Bear case: 24% overvalued

“Reliance on regulatory approvals and commercial partnerships exposes Alvotech to significant execution, revenue concentration, and approval timeline risks that could delay growth…”

Read the full Bear Case to see why Alvotech could be overvalued

Do you think there’s more to the story for Alvotech? Head over to our Community to see what others are saying!

The Bottom Line

Alvotech screens as undervalued on market multiples, yet that discount exists for clear reasons linked to execution, funding needs and regulatory risk. The gap between its current P/S and peer benchmarks only matters if the biosimilar portfolio converts into durable revenue on the timelines investors expect. For you as a shareholder or potential investor, the crux is whether that discount reflects an overly cautious market or a fair cushion for the operational and balance sheet risks already flagged. How Alvotech delivers on approvals, partnerships and financing from here will decide which side of that debate proves closer to the mark.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ALVO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com